You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Infanrix hexa logo

Product menu

Resources

Below is a range of useful tools and videos that may support your discussions
with parents and to learn more about the clinical benefits of Infanrix hexa

Latest downloads

NA

Acellular vs. whole-cell vaccines

Learn more about the differences between acellular and whole-cell pertussis vaccines

DOWNLOAD NOW

Building trust with parents

Our recently published survey revealed key insights into building trust with parents around vaccination1

While many parents and HCPs agree on several vaccine-related issues, the survey highlighted some differences in perspectives and expectations1

Increased awareness of parents’ priorities and concerns around vaccination could help you in your discussions with them, helping to build trust and, potentially, impacting on vaccine acceptance1

Watch the animation below to find out more and download the full-text manuscript

DOWNLOAD STUDY

Quick links

Safety

See how Infanrix hexa compares with a competitor in terms of local and systemic reactions

VIEW THE COMPARISON

Immune persistence

A long immune persistence can offer reassurance; see how long immune persistence of Infanrix hexa has been followed-up

See the data

Efficacy and experience

Infanrix hexa helps protect against six target diseases, with 20 years of real-world experience

SEE THE REAL WORLD EVIDENCE

Need help with this product?

Request a visit

Get in touch with a GSK representative

DT2aP, diphtheria, tetanus and acellular pertussis; ESPID, European Society For Paediatric Infectious Diseases; HBV, hepatitis B virus; Hib, Haemophilus influenzae type b; IPV, inactivated polio virus
*Indicates outcomes for which there was a statistically significant difference between Infanrix hexa and DT2aP-HBV-IPV-Hib2

References

  1. Bakhache P et al. Hum Vaccin Immunother 2021; doi:10.1080/21645515.2021.1961468.
  2. Mukherjee P et al. Exp Rev Vaccines 2021; 20:319–330.

For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via Gulf-KSA.Product-Complaints@gsk.com

Trademarks are property of their respective owners.
©2023 GSK group of companies or its licensor. All rights reserved.

PM-RCH-INH-WCNT-230001 | Date of preparation: February 2023